NCT00395174View on ClinicalTrials.gov

Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

870

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Influenza
Interventions
BIOLOGICAL

Influenza Vaccination

0.5mL dose for intramuscular injection

Trial Locations (7)

14642

Rochester Medical Center, Rochester

15241

Primary Physicians Research, Pittsburgh

21201

Center of Vaccine Development, Univ. of Maryland, Baltimore

21230

Passport Health Maryland, Baltimore

55905

Mayo Clinic College of Medicine, Rochester

77030

Baylor College of Medicine, Houston

07702

Passport Health New Jersey, Shrewsbury

All Listed Sponsors
lead

Protein Sciences Corporation

INDUSTRY

NCT00395174 - Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults | Biotech Hunter | Biotech Hunter